Zhang Chu, Poudel Ishwor, Mita Nur, Kang Xuejia, Annaji Manjusha, Lee Seungjong, Panizzi Peter, Shamsaei Nima, Fasina Oladiran, Babu R Jayachandra, Arnold Robert D
Department of Drug Discovery and Development, Harrison College of Pharmacy, Auburn University, Auburn, AL 36849, USA.
Faculty of Pharmacy, Mulawarman University, Samarinda 75119, Indonesia.
Pharmaceutics. 2025 Jul 14;17(7):911. doi: 10.3390/pharmaceutics17070911.
: Personalized 3D-printed (3DP) metallic implants delivery systems are being explored to repair bone fractures, allowing the customization of medical implants that respond to individual patient needs, making it potentially more effective and of greater quality than mass-produced devices. However, challenges associated with postsurgical infections caused by bacterial adhesion remain a clinical issue. To address this, local antibiotic therapies are receiving extensive attention to minimize the risk of implant-related infections. This study investigated the use of amikacin (AMK), a broad-spectrum aminoglycoside antibiotic, incorporated onto 3D-printed 316L stainless steel implants using biodegradable polymer coatings of chitosan and poly lactic-co-glycolic acid (PLGA). : This research examined different approaches to coat 3DP implants with amikacin. Various polymer-based coatings were studied to determine the optimal formulation based on the characteristics and release profile. The optimal formulation was performed on the antibacterial activity studies. : AMK-chitosan with PLGA coating implants controlled the rate of drug release for up to one month. The 3DP drug-loaded substrates demonstrated effective, concentration-dependent antibacterial activity against common infective pathogens. AMK-loaded substrates showed antimicrobial effectiveness for one week and inhibited bacteria significantly compared to the uncoated controls. : This study demonstrated that 3DP metal surfaces coated with amikacin can provide customizable drug release profiles while effectively inhibiting bacterial growth. These findings highlight the potential of combining 3D printing with localized delivery strategies to prevent implant-associated infections and advance the development of personalized therapies.
个性化3D打印(3DP)金属植入物输送系统正在被探索用于修复骨折,它能够定制符合个体患者需求的医用植入物,使其可能比大规模生产的设备更有效且质量更高。然而,由细菌粘附引起的术后感染相关挑战仍然是一个临床问题。为了解决这一问题,局部抗生素疗法受到广泛关注,以尽量降低植入物相关感染的风险。本研究调查了使用阿米卡星(AMK),一种广谱氨基糖苷类抗生素,通过壳聚糖和聚乳酸-羟基乙酸共聚物(PLGA)的可生物降解聚合物涂层结合到3D打印的316L不锈钢植入物上的情况。
本研究考察了用阿米卡星包覆3DP植入物的不同方法。研究了各种基于聚合物的涂层,以根据其特性和释放曲线确定最佳配方。对最佳配方进行了抗菌活性研究。
带有PLGA涂层的AMK-壳聚糖植入物可控制药物释放速率长达一个月。3DP载药基质对常见感染病原体表现出有效的、浓度依赖性的抗菌活性。载有AMK的基质显示出一周的抗菌效果,与未涂层的对照相比,能显著抑制细菌生长。
本研究表明,涂有阿米卡星的3DP金属表面可以提供可定制的药物释放曲线,同时有效抑制细菌生长。这些发现突出了将3D打印与局部给药策略相结合以预防植入物相关感染并推动个性化治疗发展的潜力。